Effects of humoral factors on left ventricular remodeling under chronic heart failure

Folia Pharmacologica Japonica

Volumn 123, Issue 2, 2004, Pages 63-70

  Kodama, Makoto ^a   Tachikawa, Hitoshi ^a   Kashimura, Takeshi ^a   Hayashi, Manabu ^a   Yoshida, Tsuyoshi ^a   Hanawa, Haruo ^a   Aizawa, Yoshifusa ^a   Nakazawa, Mikio ^b   Watanabe, Kenichi ^c  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

Author keywords

Amiodarone; Angiotensin II; Angiotensin II receptor; Chronic heart failure; Left ventricular remodeling

Indexed keywords

AMIODARONE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL FACTOR; CARDIAC MYOSIN; CATECHOLAMINE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN;

ANIMAL MODEL; AUTOIMMUNE DISEASE; CONGESTIVE CARDIOMYOPATHY; DRUG EFFECT; EXPERIMENTAL AUTOIMMUNE MYOCARDITIS; GENE REPRESSION; HEART FAILURE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE REMODELING; HEART LEFT VENTRICLE WALL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART STRESS; HEART VENTRICLE REMODELING; HEMODYNAMICS; MYOCARDITIS; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; RAT; REVIEW; TACHYCARDIA;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CHRONIC DISEASE; CYTOKINES; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; RATS; VENTRICULAR REMODELING;

EID: 1042278789     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.123.63     Document Type: Review

References (22)

1. Kostin S, Pool L, Elsasser A, et al. Myocytes die by multiple mechanisms in failing human hearts. Circ Res. 2003;92:715-724.
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
3. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
4. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669-677.
5. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001-2007.
6. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. Lancet. 1999;353:9-13.
7. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
8. Cleland JGF, Pennell DJ, Ray SG, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomized controlled trial. Lancet. 2003;362:14-21.
9. Frangogiannis NG, Shimoni S, Chang SM, et al. Active interstitial remodeling: an important process in the hibernating human myocardium. J Am Coll Cardiol. 2002;39:1468-1474.
10. Yang Z, Bove CM, French BA, et al. Angiotensin II type 2 receptor overexpression preserves left ventricular function after myocardial infarction. Circulation. 2002;106:106-111.
11. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822-828.
12. Kodama M, Hanawa H, Saeki M, et al. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res. 1994;75:278-284.
13. Tachikawa H, Kodama M, Liu H, et al. Angiotensin II type 1 receptor blocker, valsartan, prevented cardiac fibrosis in rat cardiomyopathy after autoimmune myocarditis. J Cardiovasc Pharmacol. 2003;41 Suppl 1:S105-S110.
14. Cohn JN, Tognoni G, for The Valsartan Heart Filure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
15. Kashimura T, Hayashi M, Kodama M, et al. Effects of imidapril and TA-606 on rat dilated cardiomyopathy after myocarditis. Jpn Heart J. 2003 Sep;44 (5):735-744.
16. Watanabe K, Juan W, Narasimman G, et al. Comparative effects of angiotensin II receptor blockade (candesartan) with angiotensin-converting enzyme inhibitor (quinapril) in rats with dilated cardiomyopathy. J Cardiovasc Pharmacol. 2003;41 Suppl 1:S93-S97.
17. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of cardesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet. 2003;362:759-766.
18. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet. 1994;344:493-498.
19. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
20. Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol. 2001;37:1820-1826.
21. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-1853.
22. Starling RC, McCarthy PM, Buda T, et al. Results of partial left ventriculectomy for dilated cardiomyopathy. Hemodynamic, clinical and echocardiographic observations. J Am Coll Cardiol. 2000;36:2098-2103.